MARIA CECILIA DA MATTA RIVITTI MACHADO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
79 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 79
- Alopecia Areata in Latin America: Where are We and Where are We Going?(2023) VELASQUEZ-LOPERA, Margarita M.; HERNANDEZ, Natalia; JANSEN, Angela Marie; GARCIA, Angela Londono; LUNA, Paula Carolina; RICO-RESTREPO, Mariana; SAEZ-DE-OCARIZ, Maria del Mar; TAMAYO-BUENDIA, Maria Margarita; RIVITTI-MACHADO, Maria CeciliaAlopecia areata (AA) represents an underrecognized burden in Latin America (LA), severely impacting quality of life (QoL). This impact is exacerbated by limited access to specialized dermatologic care and therapies for AA within and among nations. Many of the unmet needs for AA globally also exist in LA. The region has geographic, ethnic, cultural, and economic conditions. With new AA medicines targeting immunologic pathways on the horizon, LA must prepare regarding regulatory issues, reimbursement, awareness, and education to give adequate and timely treatment for patients with AA. To address these issues, the Americas Health Foundation convened a panel of six dermatologists from Argentina, Brazil, Colombia, and Mexico who are experts in AA and its comorbidities for a 3-day virtual meeting to discuss AA diagnosis and treatment in LA and create a manuscript offering recommendations to address discussed barriers. This publication examines unmet AA needs in LA, treatment, and innovative therapies and recommends improving AA care. Access constraints to conventional and novel medicines hinder appropriate treatments for patients. Therapy initiation delays can affect QoL, mental health, and disease progression. People with AA face stigmas, discrimination, and misconceptions owing to a lack of disease awareness. With promising new treatments for AA on the horizon, all stakeholders must coordinate efforts to enhance LA's AA management landscape and improve patient outcomes.
bookPart Albinismo(2022) MACHADO, Maria Cecilia da Matta RivittibookPart Sinais cutâneos de doenças autoinflamatórias(2022) GOMES, Laís Lopes Almeida; THIEN, Chan I; MACHADO, Maria Cecilia da Matta Rivitti- Alopecia areata and novel biologic agents: report of four cases and future directions(2021) GERLERO, Paula; DOCHE, Isabella; REBEIS, Marina; MACEDO, Thalita; RIVITTI-MACHADO, Maria C.
- Trichoscopic findings of eyebrow alopecia in patients with multibacillary leprosy(2019) DOCHE, Isabella; TOSTI, Antonella; NETO, Cyro F.; TRINDADE, Maria Angela B.; RIVITTI-MACHADO, Maria Cecilia M.; AVANCINI, Joao
- Evidence for lymphocytic inflammation in non-lesional scalp of folliculitis decalvans: an observational study of 25 patients(2022) DOCHE, I.; HORDINSKY, M. K.; VALENTE, N. S.; SOTTO, M. N.; MIOTTO, I.; REBEIS, M.; RIVITTI-MACHADO, M. C.
bookPart Genodermatoses com fotossensibilidade, poiquilodermias e progérias(2022) MACHADO, Maria Cecilia da Matta RivittibookPart Cuidados com a pele normal: recém-nascido, lactente, infância e adolescência(2022) CORRêA, Paula Yume Sato Serzedello; ANG, Patrícia Lin; MACHADO, Maria Cecilia da Matta Rivitti- Tuberous sclerosis complex: review based on new diagnostic criteria(2018) PORTOCARRERO, Larissa Karine Leite; QUENTAL, Klicia Novais; SAMORANO, Luciana Paula; OLIVEIRA, Zilda Najjar Prado de; RIVITTI-MACHADO, Maria Cecilia da MattaTuberous sclerosis complex is a multisystemic, autosomal dominant genetic disorder with complete penetrance, that can evolve with hamartomas in multiple organs, such as skin, central nervous system, kidney and lung. Due to the wide phenotypic variability, the disease is often not recognized. Tuberous sclerosis complex affects one in 10,000 newborns and most patients are diagnosed during the first 15 months of life. The diagnostic criteria for tuberous sclerosis were reviewed in 2012, at the second International Tuberous Sclerosis Complex Consensus Conference. The diagnosis is based on genetic criteria, by the identification of inactivating pathogenic mutation of tumor suppressor genes TSC1 and TSC2, and clinical criteria, including cutaneous, renal, pulmonary, cardiac and neurological manifestations. The treatment of tuberous sclerosis complex consists, mainly, in management of the symptoms caused by hamartomas and in prevention of organ failure. Multidisciplinary approach is recommended, in order to obtain better clinical outcomes.
bookPart Genodermatoses com descamação(2022) MACHADO, Maria Cecilia da Matta Rivitti